Get started
Author

Alfredo Sánchez-Hernández

Observed names: A Sánchez-Hernández, A. Sanchez Hernandez, A. Sanchez-Hernandez, A. Sánchez-Hernández, Alfredo Sanchez-Hernandez, Alfredo Sanchez‐Hernandez, Alfredo Sánchez, Alfredo Sánchez Hernández, Alfredo Sánchez-Hernandez
Observed institutions: Hospital Son Llatzer, Consorcio Hospitalario Provincial de Castellón, Grupo Español de Cáncer de Pulmón, Hospital Universitario Príncipe de Asturias, Hospital Universitario Doctor Peset, Donostiako Unibertsitate Ospitalea, Fundación Hospital Provincial de Castellón, Hospital Universitario Puerta del Mar, Hospital Universitario Son Espases, Hospital Universitario de Móstoles, Hospital Universitario Río Hortega
ORCID: 0000-0001-5826-8390
Observed ORCID: 0000-0001-5826-8390
OpenAlex ID: A5021894737
Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review
2022 · María Guirado, Elena Fernández Martín, et al. · Clinical & Translational Oncology · 59
PDF
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
2022 · Mariano Provencio, Ana Laura Ortega, et al. · JAMA Oncology · 55
PDF
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
2021 · Renata Ferrarotto, Ian Anderson, et al. · Cancer Medicine · 50
PDF
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial
2025 · Charu Aggarwal, Alex Martinez-Marti, et al. · JAMA Network Open · 39
PDF
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
2021 · Mariano Provencio, Roberto Serna-Blasco, et al. · European Journal of Cancer · 36
Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group
2021 · M. Guirado, A. Sanchez-Hernandez, et al. · Clinical & Translational Oncology · 35
PDF
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
2014 · Daniel Castellano, Luis M Antón Aparicio, et al. · Expert Opinion on Drug Safety · 28
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer
2015 · Miguel Ángel Climent, Luis León-Mateos, et al. · Critical Reviews in Oncology/Hematology · 23
Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base
2014 · Spanish Germ Cell Cancer Group (SGCCG), R. Girones, et al. · Clinical & Translational Oncology · 20
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
2023 · Cristina Candal-Pedreira, Alberto Ruano-Ravina, et al. · Archivos de Bronconeumología · 18
PDF
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial
2014 · Óscar Juan, Francisco Aparisi, et al. · Clinical Lung Cancer · 16
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
2023 · Dolores Isla, Alfredo Sánchez, et al. · Journal of Clinical Medicine · 13
PDF
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
2022 · Miguel A. Climent, Albert Font, et al. · European Journal of Cancer · 13
PDF
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
2021 · R. Serna-Blasco, E. Sánchez-Herrero, et al. · ESMO Open · 12
PDF
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
2021 · David Lorente, Casilda Llacer, et al. · European Urology · 11
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
2024 · Mariano Provencio, Lucía Robado de Lope, et al. · Lung Cancer · 10
PDF
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
2023 · Cristina Candal-Pedreira, Alberto Ruano-Ravina, et al. · ERJ Open Research · 10
PDF
Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience
2018 · Regina Gironés, Francisco Aparisi, et al. · European Journal of Cancer Care · 10
PDF
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer
2012 · Miguel A. Climent, Josep Mª Piulats, et al. · Critical Reviews in Oncology/Hematology · 9
Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
2014 · Oscar Juan, Alfredo Sánchez-Hernández, et al. · PubMed · 7
SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation
2026 · H.A. Wakelee, M.-J. Ahn, et al. · Annals of Oncology · 5
Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.
2012 · Guillermo De Velasco, Luis Anton Aparicio, et al. · Journal of Clinical Oncology · 4
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial
2026 · Jaume Capdevila, Jorge Hernando, et al. · Nature Communications · 3
PDF
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study
2025 · Ovidio Fernández, Aurea Molina, et al. · Clinical & Translational Oncology · 3
PDF
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations
2024 · Guillermo Suay, Paloma Martín-Martorell, et al. · Clinical & Translational Oncology · 3
Works count: 69
Citation count: 523
H-index: 13
I10-index: 18
Year
Topic
Type